Gemstone Biotherapeutics LLC, Baltimore, Maryland, recently obtained exclusive license for new wound-healing technology from Johns Hopkins University, Baltimore. The technology may have the potential to provide a new treatment option for older patients with chronic, diabetes-related wounds. The product will specifically target diabetic foot ulcers.
Researchers have identified a mitochondrial angiotensin receptor system that becomes less functional with age and also discovered that angiotensin receptor blockers, a category of drugs approved by the FDA for hypertension, can reinvigorate this system. With these findings, they have developed a topical agent to target the biology that inhibits wound healing in older patients with diabetes.
The new license will allow Gemstone Biotherapeutics to develop and market advanced wound-healing solutions.
Information: www.gemstonebio.comCopyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.